Navigation Links
Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
Date:7/10/2012

SAN DIEGO, July 10, 2012 /PRNewswire/ -- Cylene Pharmaceuticals today announced that research collaborators at the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia have established, for the first time, that RNA Polymerase I (Pol I) activity is essential for cancer cell survival and that its inhibition selectively activates p53 to kill tumors.  Published today in Cancer Cell, the findings show that Cylene's Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant but not in normal cells.

The researchers repeated these studies with in vivo models of blood cancers and demonstrated that the drug removed malignant cells from the bloodstream, while allowing normal healthy blood cells to grow, thus differentiating CX-5461 from genotoxic treatments. Targeting cancer's dependence upon Pol I to trigger cancer-specific activation of p53 signifies an entirely new approach to cancer therapy.

"The Pol I program represents the total package. Dr. Ross Hannan, Associate Professor and Group Leader at Peter Mac's Growth Regulation Laboratory, performed elegant studies to validate Pol I as a cancer target, Cylene created CX-5461 as the first selective small molecule inhibitor of Pol I, and together we showed that this approach potently kills malignant cells through activation of p53," stated William G. Rice, PhD, President and CEO of Cylene Pharmaceuticals. "Building on our mechanistic understanding of CX-5461, we have identified specific genetic markers to select patient populations with the most sensitive solid tumor or hematological cancers."

"The combination of cancer's reliance on Pol I, the impressive preclinical activity of CX-5461, the development of clear predictive and prognostic biomarkers and the novelty of the therapeutic strategy is compelling," continued Dr. Rice.  "As such, a First-in-Human clinical trial with CX-5461 is planned in collaboration with our colleagues at Peter Mac later this year."

The Cancer Cell publication highlighted a number of potential competitive advantages of CX-5461.  An unanticipated finding was that malignant cells are considerably more dependent upon maintenance of high levels of Pol I activity than previously believed, and even modest inhibition of Pol I triggers cancer cell death. These results suggest that selective activation of a surveillance pathway to activate p53, using Pol I inhibitors such as CX-5641, is likely to be therapeutically useful in the treatment of a wide range of tumors. In addition, as a cancer-specific inducer of p53, CX-5461 was shown to be 300 times more potent than currently studied non-genotoxic p53 activators with alternate mechanisms.

About Pol I and CX-5461 CX-5461 is a first-in-class, selective small molecule inhibitor of RNA polymerase I (Pol I) that triggers a stress surveillance pathway to activate p53 in cancer cells. The tumor suppressor protein p53, known as "the guardian of the genome," orchestrates cellular responses to diverse stress factors. Activation of this protein can lead to cell cycle arrest or cell death and it is pivotal in determining whether cancer cells proliferate or die. CX-5461 inhibits upregulated Pol I transcription in cancer cells, causing the release of ribosomal proteins (RP) from the nucleolus. These RP then bind to Mdm2, liberating p53 from the Mdm2-p53 complex to induce apoptosis in cancer cells. Non-genotoxic activation of p53 has long been an attractive approach to treating cancers, but it has not yet been successfully exploited in the clinic. CX-5461 has therapeutic potential in both solid tumor and hematological malignancies, yet hematologic cancers, the vast majority of which have wild-type p53 status, are exquisitely sensitive to CX-5461 and represent the clearest path to clinical proof of concept.

About Cylene Pharmaceuticals Cylene Pharmaceuticals is a clinical stage private company developing small molecule drugs against newly validated targets in essential cancer pathways.  Cylene's leadership in exploiting CK2 pathways enables rational drug combinations for improved treatment outcomes against many cancer indications.  The Company's Pol I program provides a non-genotoxic mechanism for activating p53 to kill cancer cells.  Cylene's unique approaches deliver innovative cancer agents that can enable pharmaceutical companies to expand their portfolios and extend the efficacy, lifecycle and reach of current cancer therapeutics. For more information on Cylene and its programs, please visit www.cylenepharma.com.

For more information and images, quotes and links, please visit the social media news release at http://bit.ly/NE040v.


'/>"/>
SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
2. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
3. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
4. Global Kidney Cancer Drugs Industry
5. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
6. Prostate Cancer Center of New Jersey the Latest Center to Achieve High Honor of ACR-ASTRO Accreditation
7. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
8. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
9. Aethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available
10. Elektas Gamma Knife and Radiation Therapy Systems for Cancer Treatment Take Top Three Places in 2012s Best in KLAS for Radiation Therapy
11. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... Fla. , May 22, 2017  As ... as a whole continue to make the revolutionary ... becomes increasingly important for ensuring positive patient outcomes ... industry stakeholders are shifting focus away from clinical ... and effects of long-term specialty drug therapy utilization ...
(Date:5/18/2017)... 2017  Bayer announced today that the latest research ... at the 53 rd Annual Meeting of the ... 2-6 in Chicago . ... colorectal, liver and thyroid cancers, as well as lymphomas, ... CHRONOS-1 trial of copanlisib in patients with relapsed or ...
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a privately-held ... and developing novel compounds to treat Parkinson,s disease (PD), has ... is a Phase 1/2a randomized, controlled, multicenter study involving patients ... will enroll 50 patients over a 9-to-12-month period. The first ... 10 patients with PD. Participating sites include Denver ...
Breaking Medicine Technology:
(Date:5/26/2017)... Plano, Texas (PRWEB) , ... May 26, 2017 , ... ... Cord Stimulation System, a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita ... , “We are pleased to be the first in Arkansas to introduce the ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: ... FAMILY-Our Journey to the Cross” is the creation of published authors, Bob and Margaret Massey. ... used to say, he is "panther quick and leather tough." His love for others ...
(Date:5/26/2017)... ... ... Water damage to the flooring of several classrooms at The Fort Lee Elementary ... number of critical issues to address before students could return to classes. , First, ... no disruption to class schedules. Second, the project had to comply with New Jersey ...
Breaking Medicine News(10 mins):